Cytokinetics, Inc. (NASDAQ:CYTK) CEO Robert I. Blum sold 4,000 shares of the business’s stock in a transaction on Friday, October 5th. The stock was sold at an average price of $8.79, for a total value of $35,160.00. Following the completion of the sale, the chief executive officer now directly owns 160,022 shares in the company, valued at approximately $1,406,593.38. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Shares of Cytokinetics stock opened at $8.60 on Friday. The firm has a market cap of $538.09 million, a PE ratio of -3.32 and a beta of 1.41. The company has a current ratio of 8.95, a quick ratio of 8.95 and a debt-to-equity ratio of 0.41. Cytokinetics, Inc. has a 12-month low of $6.20 and a 12-month high of $15.95.

Cytokinetics (NASDAQ:CYTK) last announced its earnings results on Thursday, July 26th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.51). The company had revenue of $6.22 million for the quarter, compared to analyst estimates of $5.54 million. Equities research analysts predict that Cytokinetics, Inc. will post -2.03 EPS for the current fiscal year.

A number of analysts have recently commented on CYTK shares. BidaskClub raised Cytokinetics from a “hold” rating to a “buy” rating in a research note on Saturday, September 8th. Morgan Stanley started coverage on Cytokinetics in a research note on Monday, September 10th. They issued an “equal weight” rating and a $10.00 price objective on the stock. Zacks Investment Research downgraded Cytokinetics from a “buy” rating to a “hold” rating in a research note on Tuesday, July 17th. Cantor Fitzgerald reissued a “hold” rating and issued a $10.00 price objective on shares of Cytokinetics in a research note on Sunday, June 17th. Finally, HC Wainwright boosted their price objective on Cytokinetics to $24.00 and gave the stock a “buy” rating in a research note on Monday, June 18th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. Cytokinetics currently has an average rating of “Buy” and a consensus target price of $13.00.

Several institutional investors have recently made changes to their positions in CYTK. DRW Securities LLC acquired a new stake in shares of Cytokinetics during the first quarter worth $101,000. Fox Run Management L.L.C. raised its position in shares of Cytokinetics by 181.8% during the second quarter. Fox Run Management L.L.C. now owns 31,627 shares of the biopharmaceutical company’s stock worth $263,000 after purchasing an additional 20,405 shares during the period. A.R.T. Advisors LLC acquired a new stake in shares of Cytokinetics during the first quarter worth $350,000. Employees Retirement System of Texas acquired a new stake in shares of Cytokinetics during the first quarter worth $360,000. Finally, UBS Group AG raised its position in shares of Cytokinetics by 226.7% during the first quarter. UBS Group AG now owns 54,910 shares of the biopharmaceutical company’s stock worth $396,000 after purchasing an additional 38,105 shares during the period. 68.45% of the stock is currently owned by institutional investors.

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is developing small molecule drug candidates primarily engineered to increase muscle function and contractility.

Further Reading: Book Value Per Share in Stock Trading

Insider Buying and Selling by Quarter for Cytokinetics (NASDAQ:CYTK)

Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.com's FREE daily email newsletter.